ClinicalTrials.gg
CompletedNCT01444092Updated Jan 6, 2022Results posted

Safety Study of Entocort for Children With Crohn's Disease

A Phase 3 interventional study of Entocort in Crohn's Disease, sponsored by Padagis LLC. Completed at 24 sites in 5 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by Padagis LLC · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 660 studies in Crohn Disease with a site in United States — 122 open to participants now, 163 under way, 35 of them phase 3. Crohn Disease · United States.

Enrollment
178th of 528
123 · median 60
Started
2011
with 32 others
Phase 3
124 of 660
21 open now
Registered
192nd of 660
by date

Among the 660 studies in Crohn Disease with a site in United States, this one is the 178th largest by enrollment of the 528 interventional ones that give a count, is one of 33 that started in 2011, is one of 124 in phase 3, and was the 192nd registered.

Crohn Disease

1,994 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

122 of the 660 studies in Crohn Disease with a site in United States are open now. Recruiting first, the newest first:

117 more — sign in →

All 122 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 660 studies in Crohn Disease with a site in United States, or all of them as a file.
02

Study summary

A Safety Study using Entocort EC for children with mild to moderate Crohn's Disease

Read the detailed description

A Multicenter, Open label, Non-comparative Study to Evaluate the Safety of Entocort EC for the Treatment of Crohn's Disease in Paediatric Subjects Aged 5 to 17 Years, Inclusive

03

Conditions studied

  • Crohn's Disease

Browse trials for

04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All male and female subjects must be aged 5 to 17, inclusive, and must not have reached their 18th birthday by the estimated final office visit.
  • Subject must be diagnosed with active Crohn's disease of the ileum and/or ascending colon confirmed by endoscopic and/or radiographic evidence, and/or evidence of mucosal erosions and/or histology.
  • Subjects with mild to moderate Crohn's disease.
  • All subjects must have a stool analysis negative for Clostridium difficile toxin, Yersinia enterolytica, Campylobacter jejuni, Salmonella, Shigella, within the 30 days prior to visit 1.
  • All subjects must have had laboratory assessments within 7 days prior to visit 1.
  • All subjects must weigh >= 15 kg at time of enrollment

Exclusion criteria

Exclusion Criteria:

  • Subjects who have had any previous intestinal resection proximal to and including the ascending colon
  • Subjects with evidence of severe active Crohn's disease and/or, stricturing and prestenotic dilatation, clinical evidence of obstruction, perirectal abscess, perirectal disease with active draining fistulas, perforation, or any septic complications
  • Subjects who do not have a negative stool analysis, within the 30 days prior to visit 1
  • Subjects who have been screened/or enrolled in this study previously within the last 30 days
  • Subjects with morning cortisol level \<150 nmol/l (5.4 ug/dl) or DHEA-S below normal range for age and gender
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Entocort

    Study Medication

    Drug: Entocort

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Event

    Number of patients with at least one adverse event

    Time frame: 12 weeks

Secondary outcomes

  1. PCDAI

    Paediatric Crohn's Disease Activity Index. Range from 0 (best) to 100 (worst).

    Time frame: Baseline to 8 weeks

  2. IMPACT 3

    IMPACT 3 is a self-administered QoL form. The score ranges from 35 (poor) to 175 (best).

    Time frame: Baseline to 8 weeks

07

Results

Posted Aug 11, 2016

Participant flow

123 patients were screened/enrolled, but only 108 received treatment. The other 15 did not meet the inclusion/exclusion criteria. They only appear in the disposition tables in the CSR (Tables 8 and 10) and did not "start" in the study.

Participant flow — Overall Study
MilestoneEntocort
Started108
Informed consent obtained108
Completed91
Not completed17
Withdrew: Adverse event8
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject1
Withdrew: Other eligibility criteria7

Outcome measures

PrimaryAdverse Event

Number of patients with at least one adverse event

Time frame:
12 weeks
Reported as:
Number · Patients
Adverse Event
PatientsEntocort
Adverse Event79
SecondaryPCDAI

Paediatric Crohn's Disease Activity Index. Range from 0 (best) to 100 (worst).

Time frame:
Baseline to 8 weeks
Reported as:
Mean · Units on a scale
PCDAI
Units on a scaleEntocort
Baseline (Day1)19.10 ± 10.1
Change after 8 weeks-10.0 ± 10.1
SecondaryIMPACT 3

IMPACT 3 is a self-administered QoL form. The score ranges from 35 (poor) to 175 (best).

Time frame:
Baseline to 8 weeks
Reported as:
Mean · Units on a scale
IMPACT 3
Units on a scaleEntocort
Baseline (Day 1)132.1 ± 18.8
Change after 8 weeks7.8 ± 13.3

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Entocort—8/108 (7.4%)78/108 (72.2%)
Most frequent serious events
Most frequent serious events
EventEntocort
Crohn's diseaseGastrointestinal disorders4/108
Diarrhoea haemorrhagicGastrointestinal disorders1/108
Small intestinal obstructionGastrointestinal disorders1/108
HypokalaemiaMetabolism and nutrition disorders1/108
Musculoskeletal chest painMusculoskeletal and connective tissue disorders1/108
Erythema nodosumSkin and subcutaneous tissue disorders1/108
Most frequent other events
Showing 10 of 107
Most frequent other events
EventEntocort
Increased appetiteMetabolism and nutrition disorders17/108
Abdominal painGastrointestinal disorders16/108
AcneSkin and subcutaneous tissue disorders15/108
IrritabilityPsychiatric disorders14/108
CushingoidEndocrine disorders13/108
HeadacheNervous system disorders9/108
Crohn's diseaseGastrointestinal disorders7/108
NauseaGastrointestinal disorders6/108
Decreased appetiteMetabolism and nutrition disorders6/108
InsomniaPsychiatric disorders6/108

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Entocort
Mean13.7 ± 2.41
Age, Customized
Age, Customized(Participants)Entocort
=<8 Yrs5
>8 Yrs103
Sex: Female, Male
Sex: Female, Male(Participants)Entocort
Female51
Male57
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entocort
Asian1
Black Or African American4
Other3
White100
08

Study locations

24 sites
  • Research Site
    Aurora, Colorado, United States
  • Research Site
    Atlanta, Georgia, United States
  • Research Site
    Chicago, Illinois, United States
  • Research Site
    Oak Lawn, Illinois, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Saint Paul, Minnesota, United States
  • Research Site
    Mays Landing, New Jersey, United States
  • Research Site
    Morristown, New Jersey, United States
  • Research Site
    Buffalo, New York, United States
  • Research Site
    Greenville, North Carolina, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Halifax, Nova Scotia, Canada
  • Research Site
    London, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    München, Germany
  • Research Site
    Firenze, Italy
  • Research Site
    Messina, Italy
  • Research Site
    Napoli, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Kraków, Poland
  • Research Site
    Rzeszów, Poland
  • Research Site
    Warszawa, Poland
  • Research Site
    Wrocław, Poland
  • Research Site
    Łódź, Poland
09

References and documents

Publications

  • Cohen SA, Aloi M, Arumugam R, Baker R, Bax K, Kierkus J, Koletzko S, Lionetti P, Persson T, Eklund S. Enteric-coated budesonide for the induction and maintenance of remission of Crohn's disease in children. Curr Med Res Opin. 2017 Jul;33(7):1261-1268. doi: 10.1080/03007995.2017.1313213. Epub 2017 Apr 19. PubMed 28420280 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Sep 2014 and a completion of Sep 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2011
First posted
Sep 30, 2011
Start
Nov 2011
Primary completionActual
Sep 2014
CompletionActual
Sep 2014
Results first posted
Aug 11, 2016
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01444092
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Sep 30, 2011
Start date
Nov 2011
Primary completion
Sep 2014
Completion
Sep 2014
Results posted
Aug 11, 2016
Last update
Jan 6, 2022

Study contacts

Stanley Cohen, MD
principal investigator · Children's Center for Digestive Healthcare, LLC, Atlanta, Georgia, USA and Emory University School of Medicine, Atlanta, Georgia, USA
Stefan Eklund, MD
study director · AstraZeneca Pharmaceuticals, Mölndal, Sweden
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion